Giftify, Inc. Reports Surge in Pharmacy Retailer Gift Card Demand Following GLP-1 Medication Savings Initiative
Giftify (NASDAQ: GIFT) reported a dramatic surge in pharmacy retailer gift card sales through its CardCash.com platform, with a 916% week-over-week increase in face value across major pharmacy retailers like CVS and Walgreens. The surge follows the company's introduction of a smart savings program for GLP-1 medications including Ozempic and Zepbound.
To meet growing demand, the company has significantly expanded its inventory levels, with CVS inventory growing 120% year-over-year and Walgreens inventory increasing by 736%. The initiative aims to provide cost-saving solutions for consumers purchasing high-cost prescription medications while also addressing seasonal health product demands.
Giftify (NASDAQ: GIFT) ha riportato un drammatico aumento delle vendite di carte regalo nei rivenditori di farmacia attraverso la sua piattaforma CardCash.com, con un aumento del 916% settimana dopo settimana nel valore nominale presso i principali rivenditori di farmacia come CVS e Walgreens. Questo incremento segue l'introduzione da parte dell'azienda di un programma di risparmio intelligente per i farmaci GLP-1, tra cui Ozempic e Zepbound.
Per far fronte alla crescente domanda, l'azienda ha significativamente ampliato i suoi livelli di inventario, con l'inventario di CVS che cresce del 120% anno su anno e l'inventario di Walgreens che aumenta del 736%. L'iniziativa mira a fornire soluzioni di risparmio per i consumatori che acquistano farmaci prescritti ad alto costo, affrontando anche la domanda stagionale di prodotti per la salute.
Giftify (NASDAQ: GIFT) informó un aumento dramático en las ventas de tarjetas de regalo de minoristas de farmacias a través de su plataforma CardCash.com, con un aumento del 916% semana a semana en el valor nominal en importantes minoristas de farmacia como CVS y Walgreens. Este aumento sigue a la introducción por parte de la empresa de un programa de ahorro inteligente para medicamentos GLP-1, incluyendo Ozempic y Zepbound.
Para satisfacer la creciente demanda, la empresa ha ampliado significativamente sus niveles de inventario, con el inventario de CVS creciendo un 120% interanual y el inventario de Walgreens aumentando en un 736%. La iniciativa tiene como objetivo proporcionar soluciones de ahorro para los consumidores que compran medicamentos recetados de alto costo, al mismo tiempo que aborda la demanda estacional de productos de salud.
Giftify (NASDAQ: GIFT)는 CardCash.com 플랫폼을 통해 약국 소매점의 기프트 카드 판매가 극적으로 증가했다고 보고했으며, CVS 및 Walgreens와 같은 주요 약국 소매점에서 주간 916% 증가라는 얼굴 가치를 기록했습니다. 이 증가는 Ozempic과 Zepbound를 포함한 GLP-1 약물에 대한 스마트 절약 프로그램을 회사가 도입한 후 발생했습니다.
증가하는 수요에 대응하기 위해 회사는 재고 수준을 크게 확장했으며, CVS의 재고는 전년 대비 120% 증가하고 Walgreens의 재고는 736% 증가했습니다. 이 이니셔티브는 고비용 처방약을 구매하는 소비자에게 비용 절감 솔루션을 제공하고, 계절 건강 제품 수요를 해결하는 것을 목표로 하고 있습니다.
Giftify (NASDAQ: GIFT) a rapporté une augmentation spectaculaire des ventes de cartes-cadeaux chez les détaillants de pharmacie via sa plateforme CardCash.com, avec une augmentation de 916% d'une semaine sur l'autre de la valeur faciale chez des détaillants de pharmacie majeurs tels que CVS et Walgreens. Cette hausse fait suite à l'introduction par l'entreprise d'un programme d'épargne intelligent pour les médicaments GLP-1, y compris Ozempic et Zepbound.
Pour répondre à la demande croissante, l'entreprise a considérablement élargi ses niveaux de stock, avec le stock de CVS augmentant de 120% d'une année sur l'autre et le stock de Walgreens augmentant de 736%. L'initiative vise à fournir des solutions d'économie pour les consommateurs achetant des médicaments prescrits coûteux tout en répondant également à la demande saisonnière de produits de santé.
Giftify (NASDAQ: GIFT) berichtete von einem dramatischen Anstieg der Verkaufszahlen von Geschenkkarten bei Apothekenhändlern über seine Plattform CardCash.com, mit einem Woche-zu-Woche-Anstieg von 916% im Nennwert bei großen Apothekenhändlern wie CVS und Walgreens. Der Anstieg folgt auf die Einführung eines intelligenten Sparprogramms für GLP-1-Medikamente, einschließlich Ozempic und Zepbound.
Um der wachsenden Nachfrage gerecht zu werden, hat das Unternehmen seine Lagerbestände erheblich erhöht, wobei das CVS-Lager um 120% im Jahresvergleich gewachsen ist und das Walgreens-Lager um 736% gestiegen ist. Die Initiative zielt darauf ab, kostensparende Lösungen für Verbraucher anzubieten, die hochpreisige verschreibungspflichtige Medikamente kaufen, und gleichzeitig der saisonalen Nachfrage nach Gesundheitsprodukten gerecht zu werden.
- 916% week-over-week increase in pharmacy gift card sales
- 120% year-over-year growth in CVS inventory
- 736% increase in Walgreens inventory
- Strategic expansion into healthcare sector showing immediate results
- None.
Insights
Giftify's 916% week-over-week increase in pharmacy retailer gift card sales represents a noteworthy operational achievement that directly impacts revenue potential. This surge follows their strategic entry into healthcare cost-containment solutions for expensive GLP-1 medications like Ozempic and Zepbound.
The company's substantial inventory expansion for major pharmacy chains (CVS up 120% YoY and Walgreens up 736%) demonstrates management's confidence in sustained demand and represents a calculated financial commitment to support continued growth. This inventory investment is a double-edged sword - enabling capture of accelerating sales but temporarily impacting cash flow.
This initiative intelligently positions Giftify at the intersection of two high-growth markets: discount gift cards and healthcare cost management for specialty medications. The GLP-1 medication market represents a significant opportunity, with these drugs often costing patients hundreds to thousands monthly without insurance coverage.
From a financial perspective, while percentage increases are impressive, investors should consider absolute dollar impact to assess materiality. Gift card exchange platforms typically operate on thin margins, so volume scaling is essential for meaningful profit contribution. The strategy creates potential for recurring customer relationships through prescription refills, enhancing customer lifetime value and revenue predictability.
This development demonstrates Giftify's ability to identify and rapidly capitalize on emerging consumer needs while leveraging their existing platform infrastructure, suggesting improved operational efficiency and market responsiveness.
Giftify's pharmacy gift card program addresses a critical pain point in the modern healthcare landscape - affordability of breakthrough GLP-1 medications. Drugs like Ozempic and Zepbound represent a revolutionary approach to diabetes management and weight loss, but their high retail prices (often
The 916% sales surge indicates substantial unmet consumer demand for cost-reduction solutions in this medication category. What's particularly strategic about this initiative is its timing - coinciding with both GLP-1 prescription growth and seasonal health product purchasing, creating a powerful dual sales driver.
The company's significant inventory expansion suggests they've secured reliable supply chains with major pharmacy retailers, establishing an important competitive advantage in the gift card secondary market. Their ability to maintain adequate inventory levels while experiencing exponential demand growth demonstrates operational sophistication.
Beyond immediate financial impact, this positions Giftify as a participant in the healthcare affordability ecosystem. The GLP-1 medication category continues expanding as these drugs receive additional FDA approvals for new indications and growing off-label usage. As healthcare consumers become increasingly price-sensitive and digitally-savvy in seeking cost-saving solutions, Giftify's platform is now established as a resource.
This initiative cleverly leverages their existing technology platform to address healthcare affordability without requiring regulatory approvals or healthcare partnerships, allowing rapid market entry and scalability.
Record Inventory Increase Meets Growing Consumer Demand for Healthcare Cost-Saving Solutions
Surge Driven by Ozempic and Zepbound Prescription Savings Opportunities Combined with Seasonal Health Product Purchases
SCHAUMBURG, IL, March 12, 2025 (GLOBE NEWSWIRE) -- Giftify, Inc. (NASDAQ: GIFT) (the "Company"), the owner and operator of CardCash.com and Restaurant.com, and a leader in the incentives and rewards industry, today announced a significant increase in gift card sales following its announcement of a smart savings program for GLP-1 diabetes and weight loss medications.
CardCash.com, Giftify's secondary gift card exchange platform, experienced an overall
"The response to our pharmacy gift card savings initiative has exceeded our expectations," said Ketan Thakker, CEO of Giftify, Inc. "This significant growth demonstrates the value proposition of our business model and validates our strategic expansion into the healthcare sector.”
To meet this growing demand, we have significantly increased our inventory levels:
- CVS inventory levels grew by
120% year-over-year; - Walgreens inventory experienced a remarkable
736% increase.
This inventory expansion ensures CardCash can continue to meet consumer needs while maintaining competitive discount rates.
"Our latest promotional efforts have resonated strongly with consumers, leading to a measurable increase in sales activity," said Carol Rosenblum, Marketing Manager at CardCash.com. "We are committed to supporting our customers by not only offering savings on essential medications like Ozempic and Zepbound, but also ensuring convenient access to gift card solutions across our retail partners during this peak season for health-related product purchasing."
The Company has placed increased emphasis on its pharmacy gift card program to address the growing critical need for improved preventive care and affordable access to newer treatment options. By providing practical tools to reduce prescription costs, CardCash.com supports broader healthcare accessibility while expanding Giftify's market reach.
About Giftify, Inc.
Giftify, Inc. is a pioneer in the incentive and rewards industry with a focus on retail, dining & entertainment experiences, as the owner and operator of leading digital platforms, CardCash.com and Restaurant.com. CardCash.com is a leading secondary gift card exchange platform, allowing consumers and retailers to realize value by buying and selling gift cards at various scales. Its Restaurant.com is the nation’s largest restaurant-focused digital deals brand. Restaurant.com and our Corporate Incentives division connect digital consumers, businesses and communities offering thousands of dining, retail and entertainment deals options nationwide at over 184,000 restaurants and retailers. Restaurant.com prides itself on offering the best deal, every meal. Our gift cards and restaurant certificates allow customers to save at thousands of restaurants across the country with just a few clicks.
For more information, visit: www.giftifyinc.com and www.cardcash.com and https://www.restaurant.com.
Forward-Looking Statements
Press Releases may include forward-looking statements. In particular, the words “believe,” “may,” “could,” “should,” “expect,” “anticipate,” “estimate,” “project," "propose," "plan," "intend," and similar conditional words and expressions are intended to identify forward-looking statements. Any statements made in this news release about an action, event or development, are forward-looking statements. Such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the company. Accordingly, you should not place undue reliance on these forward-looking statements. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that its forward-looking statements will prove to be correct. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. The forward-looking statements in this press release are made as of the date hereof. The company takes no obligation to update or correct its own forward-looking statements, except as required by law or those prepared by third parties that are not paid by the company. Statements in this press release that are not historical fact may be deemed forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although Giftify, Inc. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, Giftify, Inc. is unable to give any assurance that its expectations will be attained. Factors that could cause actual results to differ materially from expectations include the company’s ability identify a suitable business model for the corporation.
Investors Contacts:
IR@giftifyinc.com
FAQ
What caused the 916% increase in Giftify's (GIFT) pharmacy gift card sales?
How much did Giftify (GIFT) increase its pharmacy gift card inventory in 2025?
What medications are included in Giftify's (GIFT) pharmacy savings program?
Which pharmacy retailers are participating in Giftify's (GIFT) gift card program?
